

# Sarcoma Disease-Oriented Team

---

Clinical Research Treatment Trial Flowchart



Enter in Disease Site Name

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

First Line

Second Line

Recurrent

**UCI 21-03**  
 Pembrolizumab + Stereotactic Body Radiation Therapy  
 Coord: N. Arechiga  
 Accrual: 4/6

**EA7211**  
 Surgery + Doxorubicin, Ifosfamide or  
 Doxorubicin, Decarbazine  
 Coord: B. Huynh  
 Accrual: 0/5

**ETCTN 10556**  
 Ipilimumab and Nivolumab +/-  
 Cabozantinib  
 Coord: B. Huynh  
 Accrual: 1/5